FOLD
Price
$9.65
Change
+$0.11 (+1.15%)
Updated
Jan 23, 04:59 PM (EDT)
Capitalization
2.85B
34 days until earnings call
PLX
Price
$2.43
Change
+$0.06 (+2.53%)
Updated
Jan 23, 04:14 PM (EDT)
Capitalization
174.51M
49 days until earnings call
Ad is loading...

FOLD vs PLX

Header iconFOLD vs PLX Comparison
Open Charts FOLD vs PLXBanner chart's image
Amicus Therapeutics
Price$9.65
Change+$0.11 (+1.15%)
Volume$53.1K
Capitalization2.85B
Protalix BioTherapeutics
Price$2.43
Change+$0.06 (+2.53%)
Volume$889
Capitalization174.51M
FOLD vs PLX Comparison Chart
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. PLX commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Hold and PLX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (FOLD: $9.54 vs. PLX: $2.37)
Brand notoriety: FOLD and PLX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 68% vs. PLX: 89%
Market capitalization -- FOLD: $2.85B vs. PLX: $174.51M
FOLD [@Biotechnology] is valued at $2.85B. PLX’s [@Biotechnology] market capitalization is $174.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whilePLX’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • PLX’s FA Score: 0 green, 5 red.
According to our system of comparison, PLX is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 2 TA indicator(s) are bullish while PLX’s TA Score has 4 bullish TA indicator(s).

  • FOLD’s TA Score: 2 bullish, 3 bearish.
  • PLX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PLX is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а +2.91% price change this week, while PLX (@Biotechnology) price change was +9.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.92%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was -1.05%.

Reported Earning Dates

FOLD is expected to report earnings on May 07, 2025.

PLX is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (+3.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($2.85B) has a higher market cap than PLX($175M). PLX YTD gains are higher at: 26.064 vs. FOLD (1.274). PLX has higher annual earnings (EBITDA): -6.48M vs. FOLD (-9.2M). FOLD has more cash in the bank: 250M vs. PLX (27.4M). PLX has less debt than FOLD: PLX (5.68M) vs FOLD (445M). FOLD has higher revenues than PLX: FOLD (494M) vs PLX (45.7M).
FOLDPLXFOLD / PLX
Capitalization2.85B175M1,629%
EBITDA-9.2M-6.48M142%
Gain YTD1.27426.0645%
P/E RatioN/A13.00-
Revenue494M45.7M1,081%
Total Cash250M27.4M912%
Total Debt445M5.68M7,829%
FUNDAMENTALS RATINGS
FOLD vs PLX: Fundamental Ratings
FOLD
PLX
OUTLOOK RATING
1..100
2232
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
7935
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PLX's Valuation (65) in the Servicestothe Health Industry industry is in the same range as FOLD (76) in the Biotechnology industry. This means that PLX’s stock grew similarly to FOLD’s over the last 12 months.

PLX's Profit vs Risk Rating (100) in the Servicestothe Health Industry industry is in the same range as FOLD (100) in the Biotechnology industry. This means that PLX’s stock grew similarly to FOLD’s over the last 12 months.

PLX's SMR Rating (95) in the Servicestothe Health Industry industry is in the same range as FOLD (98) in the Biotechnology industry. This means that PLX’s stock grew similarly to FOLD’s over the last 12 months.

PLX's Price Growth Rating (35) in the Servicestothe Health Industry industry is somewhat better than the same rating for FOLD (79) in the Biotechnology industry. This means that PLX’s stock grew somewhat faster than FOLD’s over the last 12 months.

PLX's P/E Growth Rating (99) in the Servicestothe Health Industry industry is in the same range as FOLD (100) in the Biotechnology industry. This means that PLX’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDPLX
RSI
ODDS (%)
N/A
Bearish Trend 16 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 16 days ago
72%
Bearish Trend 16 days ago
84%
Momentum
ODDS (%)
Bearish Trend 16 days ago
83%
Bullish Trend 16 days ago
87%
MACD
ODDS (%)
Bearish Trend 16 days ago
83%
Bullish Trend 16 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 16 days ago
73%
Bullish Trend 16 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 16 days ago
75%
Bullish Trend 16 days ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
73%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 25 days ago
75%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 16 days ago
76%
Aroon
ODDS (%)
N/A
Bullish Trend 16 days ago
81%
View a ticker or compare two or three
Ad is loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGGKX31.820.16
+0.51%
Victory RS Global R
JFNIX69.380.02
+0.03%
Janus Henderson Global Life Sciences I
GCSIX29.07N/A
N/A
Goldman Sachs Small Cap Eq Insghts Instl
LAVGX14.35N/A
N/A
Lord Abbett International Growth R6
BOGIX32.08-0.25
-0.77%
SGI Small Cap Core Fund I Shares

PLX and

Correlation & Price change

A.I.dvisor tells us that PLX and PCVX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PLX and PCVX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
+1.72%
PCVX - PLX
32%
Poorly correlated
-1.74%
ZNTL - PLX
31%
Poorly correlated
+0.44%
CPRX - PLX
31%
Poorly correlated
-0.22%
FOLD - PLX
31%
Poorly correlated
+0.32%
ACET - PLX
31%
Poorly correlated
-2.23%
More